Description

Seegene, Inc., a global enterprise, specializes in the development and worldwide distribution of molecular diagnostic solutions. Their comprehensive portfolio of in vitro diagnostic (IVD) assays targets a broad spectrum of conditions, including various respiratory and gastrointestinal infections, human papillomavirus (HPV), and sexually transmitted infections (STIs). They also provide diagnostic tools for tuberculosis detection, drug resistance analysis, and meningitis. A key offering is their Magicplex sepsis real-time test, designed for rapid identification of pathogens causing sepsis. Beyond infectious diseases, Seegene offers tests for specific genetic markers. These include the detection of six single nucleotide polymorphisms (SNPs) in the factor II, factor V, and MTHFR genes, as well as the BRAF mutation characteristic of papillary thyroid carcinoma, which can be identified from various sample types such as thyroid tissue, fine needle aspiration biopsies, H&E slides, and paraffin-embedded tissues. The company also provides assays for determining Apolipoprotein E genotypes and identifying the BCR/ABL fusion gene in blood and whole bone marrow samples. To support these diagnostics, Seegene supplies essential laboratory instrumentation. Their equipment range includes PCR thermal cyclers, vial cap management systems, nucleic acid extraction systems, automated liquid handling workstations that streamline workflows from nucleic acid extraction to PCR setup, and advanced real-time PCR detection systems. Founded in 2000, Seegene, Inc. is headquartered in Seoul, South Korea.